Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809

摘要

BackgroundChemotherapy-induced ovarian failure (CIOF) is a frequent side effect of adjuvant chemotherapy that results in rapid bone loss. We hypothesized that zoledronic acid (ZA), a third-generation amino bisphosphonate, would prevent bone loss in premenopausal women who developed CIOF.